Thrivent Financial For Lutherans grew its holdings in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 106,900 shares of the company’s stock after acquiring an additional 10,920 shares during the quarter. Thrivent Financial For Lutherans owned 0.28% of Aerie Pharmaceuticals worth $6,387,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of AERI. Public Employees Retirement Association of Colorado bought a new stake in shares of Aerie Pharmaceuticals during the 4th quarter valued at about $176,000. Quantbot Technologies LP boosted its stake in Aerie Pharmaceuticals by 792.5% in the 3rd quarter. Quantbot Technologies LP now owns 2,981 shares of the company’s stock worth $144,000 after purchasing an additional 2,647 shares during the period. Great West Life Assurance Co. Can boosted its stake in Aerie Pharmaceuticals by 65.0% in the 3rd quarter. Great West Life Assurance Co. Can now owns 4,160 shares of the company’s stock worth $204,000 after purchasing an additional 1,639 shares during the period. Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Aerie Pharmaceuticals during the 3rd quarter worth approximately $204,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Aerie Pharmaceuticals during the 3rd quarter worth approximately $276,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently issued reports on the company. Seaport Global Securities reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, March 5th. BidaskClub upgraded Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. HC Wainwright set a $78.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 1st. Cantor Fitzgerald set a $86.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, February 28th. Finally, Zacks Investment Research upgraded Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $78.75.
Aerie Pharmaceuticals stock traded down $0.35 during trading hours on Thursday, hitting $55.25. The stock had a trading volume of 109,808 shares, compared to its average volume of 366,873. The firm has a market cap of $2,195.80, a PE ratio of -13.56 and a beta of 0.98. The company has a current ratio of 10.09, a quick ratio of 10.09 and a debt-to-equity ratio of 0.91. Aerie Pharmaceuticals Inc has a twelve month low of $38.14 and a twelve month high of $66.60.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, February 28th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.17). research analysts forecast that Aerie Pharmaceuticals Inc will post -3.62 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Thrivent Financial For Lutherans Boosts Holdings in Aerie Pharmaceuticals Inc (AERI)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/22/thrivent-financial-for-lutherans-raises-position-in-aerie-pharmaceuticals-inc-aeri.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.